more

NuCana (NCNA)

(Delayed Data from NSDQ)

$3.81 USD

-0.03 (-0.78%)

Updated Apr 25, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now

by Zacks Equity Research Published on September 28,2023

NuCana PLC Sponsored ADR (NCNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

NCNANegative Net Change

NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research Published on November 21,2022

NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NCNANegative Net Change

Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks

by Zacks Equity Research Published on October 05,2022

NuCana PLC Sponsored ADR (NCNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

NCNANegative Net Change

NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research Published on September 28,2022

NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NCNANegative Net Change

Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)

by Zacks Equity Research Published on September 28,2022

The heavy selling pressure might have exhausted for NuCana PLC Sponsored ADR (NCNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

NCNANegative Net Change

BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on March 15,2022

On BioNTech's (BNTX) fourth-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.

biotechs

Down 57.3% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)

by Zacks Equity Research Published on March 04,2022

NCNANegative Net Change

Is NuCana PLC Sponsored ADR (NCNA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on January 24,2022

Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.

Company News for Sep 30, 2021

by Zacks Equity Research Published on September 30,2021

Companies in the news are: CTAS, NCNA, GOVX, LCID

Why NuCana (NCNA) Might Surprise This Earnings Season

by Zacks Equity Research Published on November 10,2020

NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NCNANegative Net Change

NuCana (NCNA) Surges: Stock Moves 6.3% Higher

by Zacks Equity Research Published on September 24,2020

NuCana (NCNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

medical

Should You Buy NuCana (NCNA) Ahead of Earnings?

by Zacks Equity Research Published on August 18,2020

NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NCNANegative Net Change

Co-Diagnostics (CODX) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research Published on August 11,2020

Co-Diagnostics' (CODX) second-quarter results are likely to reflect higher COVID-19 test sales.

Bionano (BNGO) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research Published on August 10,2020

Bionano's (BNGO) sales numbers will be in focus when it reports Q2 results later in the week.

Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC

by Zacks Equity Research Published on July 02,2020

Blueprint Medicines (BPMC) files an NDA to the FDA for pralsetinib to treat patients with advanced/metastatic RET mutant medullary thyroid cancer and RET fusion-positive thyroid cancers. Stock up.

biotechs

Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation

by Zacks Equity Research Published on June 29,2020

The FDA bestows a Breakthrough Therapy status on Axsome's (AXSM) AXS-05 for the treatment of Alzheimer's disease agitation. Shares rise.

biotechs

Gilead to Buy 49.9% Stake in Private Biotech for $275M

by Zacks Equity Research Published on June 24,2020

Gilead (GILD) to purchase 49.9% equity interest in privately-held Pionyr Immunotherapeutics. The company can later also exercise an option to acquire the rest of Pionyr.

biotechs

Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag

by Zacks Equity Research Published on June 18,2020

The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromatosis.

biotechs

ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis

by Zacks Equity Research Published on June 16,2020

ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.

biotechs

Immunic Gets FDA Allowance for Phase II Coronavirus Study

by Zacks Equity Research Published on June 10,2020

Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this year.